MacOlene® is a revolutionary, patented herbal composition developed to support eye health, specifically targeting conditions like age-related macular degeneration (AMD) and diabetic retinopathy. Utilizing a synergistic blend of standardized herbal extracts, MacOlene offers.
Age-related macular degeneration (AMD) affects the macula of the retina, leading to blurred vision or loss of central vision. It is a leading cause of vision loss in people over the age of 50. AMD occurs in two forms:
Dry AMD: The most common form, characterized by gradual vision loss.
Wet AMD: Less common but more severe, involving the formation of neovascularization.
VEGF (Vascular Endothelial Growth Factor) and PDGF (Platelet-Derived Growth Factor) are the major stimulators of wet AMD. While no specific treatment exists for AMD in the nutraceutical space, certain vitamin combinations with lutein and zeaxanthin are beneficial for dry AMD, and anti-VEGF injections help manage wet AMD.
MacOlene® is a cutting-edge solution for protecting and enhancing vision naturally. Trust in the science and synergy of MacOlene to support your eye health and combat the challenges of AMD and diabetic retinopathy.
First Herbal Product for AMD: MacOlene is the world’s first herbal product designed for the prevention and treatment of age-related macular degeneration.
Proven Efficacy: Demonstrated effectiveness in in vitro studies with ARPE and HUVEC cells.
Non-Vitamin Herbal Formulation: A natural alternative to vitamin-based treatments.
Standardized Natural Extracts: Ensuring consistent quality and potency
VEGF Down-Regulating Activity, VEGF Binding Activity, PDGF Inhibitory Activity, Anti-Neovascular Activity
Efficacy Studies
MacOlene’s efficacy was demonstrated in a comprehensive study using ARPE (Retinal Pigment Epithelial) and HUVEC (Human Umbilical Vein Endothelial) cell line models. These studies mimic the in vivo conditions of AMD and diabetic retinopathy, showcasing MacOlene’s significant benefits:
VEGF Down-Regulation: MacOlene® demonstrated 58.49% downregulation of VEGF in ARPE cells for oral and ophthalmic formulations, respectively.
VEGF Binding: The binding activity of MacOlene showed 83.98% binding of VEGF for oral and ophthalmic formulations, respectively.
Inhibition of Neovascularization: MacOlene significantly inhibited tube formation in HUVEC cells, indicating its effectiveness in preventing new blood vessel formation.
First Herbal Product for AMD: MacOlene® is the world’s first herbal product designed for the prevention and treatment of age-related macular degeneration.
Proven Efficacy: Demonstrated effectiveness in in vitro studies with ARPE and HUVEC cells.
Non-Vitamin Herbal Formulation: A natural alternative to vitamin-based treatments.
Standardized Natural Extracts: Ensuring consistent quality and potency.
MacOlene® can be effectively combined with lutein and zeaxanthin or the AREDS-2 (Age-Related Eye Disease Study) formula to enhance its benefits for eye health.
MacOlene + AREDS - 2 formula
MacOlene + Luein + Zeaxanthin
MacOlene’s efficacy was demonstrated in a comprehensive study using ARPE (Retinal Pigment Epithelial) and HUVEC (Human Umbilical Vein Endothelial) cell line models. These studies mimic the in vivo conditions of AMD and diabetic retinopathy, showcasing MacOlene’s significant benefits:
VEGF Down-Regulation:MacOlene demonstrated 58.49% and 59.38% downregulation of VEGF in ARPE cells for oral and ophthalmic formulations, respectively.
VEGF Binding: The binding activity of MacOlene showed 83.98% and 70.58% binding of VEGF for oral and ophthalmic formulations, respectively.
Inhibition of Neovascularization: MacOlene significantly inhibited tube formation in HUVEC cells, indicating its effectiveness in preventing new blood vessel formation.